Clinical trials: Urinary Complications
Stress Urinary Incontinence, Pelvic Organ Prolapse
Ethicon Pelvic Mesh Post Market Clinical Follow-up Registry
The objective of this post market, clinical registry is to evaluate the performance of the products of the TVT family of products or vaginal vault or uterine prolapse repair (with laparotomic or laparoscopic approach including…
- Trial name
- NCT04829175
- Testing
- Intervention
- Where
- 10 sites in United States, Austria and 5 more
- Volunteers
- 1,000 people
- Sponsor
- Ethicon, Inc.
Incontinence, Urge
T-DOC® NXT Clinical Investigation
Assessing the Performance, Safety and Usability of our Next Generation T-DOC® NXT Catheter for Performing Urodynamic Studies
- Trial name
- NCT03615001
- Testing
- TDOC NXT
- Where
- United States
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- Laborie Medical Technologies Inc.
Non-muscle Invasive Bladder Cancer (NMIBC)
Evaluating the Safety and Performance of the Eight Medical Hyperthermia System IV 1.0 for HIVEC in NMIBC.
The goal of this clinical trial is to evaluate the safety and performance of the Eight Medical Hyperthermia System IV 1.0 when used to deliver recirculating hyperthermic intravesical chemotherapy (HIVEC) with mitomycin C (MMC) in…
- Trial name
- NCT07758881
- Testing
- Hyperthermic intravesical chemotherapy (HIVEC)
- Where
- 2 sites in Belgium
- Volunteers
- 30 people
- Sponsor
- Eight Medical International BV
Advanced Solid Tumours With Androgen Receptor Pathway as a Potential Factor
Phase I Open Label Dose Escalation Study to Investigate the Safety & Pharmacokinetics of AZD5312 in Patients With Androgen Receptor Tumors
This is a first time in man (FTIM), Phase I study to determine the Maximum Tolerated Dose, Recommended Phase 2 Dose, safety, tolerability and Pharmacokinetics of AZD5312.
- Trial name
- NCT02144051
- Testing
- AZD5312
- Where
- 4 sites in United States, United Kingdom
- Volunteers
- 32 people
- Sponsor
- AstraZeneca
Overactive Bladder With Urge Urinary Incontinence
URO-902 in Female Subjects With Overactive Bladder and Urge Urinary Incontinence
This study will evaluate the efficacy, safety, and tolerability of a single dose of URO-902 24 milligrams (mg) and 48 mg (administered via intradetrusor injection), compared with placebo, in participants with overactive bladder…
- Trial name
- NCT04211831
- Testing
- URO-902
- Where
- 20 sites in United States
- Volunteers
- 80 people
- Sponsor
- Urovant Sciences GmbH
Solid Tumor, Lymphoma
Study of Oral PXD101 in Patients With Advanced Solid Tumors or Lymphoma
This is a Phase I dose escalation study of PXD101 administered orally. Oral belinostat will be given once or twice daily at various dosing schedules to patients with solid tumors.
- Trial name
- NCT00413075
- Testing
- oral belinostat
- Where
- 6 sites in United States, Denmark and 1 more
- Volunteers
- 121 people
- Sponsor
- Valerio Therapeutics
Bladder Outlet Obstruction, Lower Urinary Tract Symptoms
The Value of Multiple Urine Flow Rate Measurements in Male Benign Prostatic Hyperplasia (BPH) Subjects
Crossover comparison of different flow meters with a digital home flow meter as a reference. Main hypothesis: Reapeated home flow measurements with a disposable device will provide a better understanding of the patients urinary…
- Trial name
- NCT00710749
- Testing
- Disposable device, Digital device, Clinic flow measurement
- Where
- 4 sites in United States, Netherlands and 2 more
- Volunteers
- 60 people
- Sponsor
- Wellspect HealthCare
Diabetes, Bladder Cancer
Cohort Study of Pioglitazone and Bladder Cancer in Patients With Type II Diabetes
To assess the potential association between pioglitazone and bladder cancer compared with non-pioglitazone users among patients with type 2 diabetes mellitus.
- Trial name
- NCT01637935
- Testing
- Pioglitazone
- Volunteers
- 193,099 people
- Sponsor
- Takeda
Stress Urinary Incontinence
GTx-024 as a Treatment for Stress Urinary Incontinence in Women
The purpose of this study is to determine whether GTx-024 is safe and effective in the treatment of stress urinary incontinence in postmenopausal women.
- Trial name
- NCT02658448
- Testing
- GTx-024
- Where
- 3 sites in United States
- Volunteers
- 19 people
- Sponsor
- GTx
Urologic Diseases, Urodynamics
Trial for Reliability of Urodynamics SysTem
The goal of this prospective trial is to assess the safety and reliability of the Glean Urodynamics System (GUS) in adult females with lower urinary tract symptoms.
- Trial name
- TRUST-1 (NCT05694793)
- Testing
- Glean Urodynamics System
- Where
- 3 sites in United States
- Volunteers
- 30 people
- Sponsor
- Bright Uro
Overactive Bladder (OAB)
A Phase II Study of KUC-7483 in Patients With Overactive Bladder
To investigate the efficacy and safety of KUC-7483 in overactive bladder patients.
- Trial name
- NCT00742833
- Testing
- KUC-7483
- Where
- 6 sites in Japan
- Volunteers
- 400 people
- Sponsor
- Kissei Pharmaceutical Co., Ltd.
Recurrent or Metastatic Cancer, Head and Neck Cancer
Safety and Efficacy of FalateScan (Technetium Tc 99m EC20) in Patients With Known Suspected Recurrent or Metastatic Cancer From a Solid Tumor
The folate receptor is over-expressed on many types of cancer cells and new folate receptor targeted therapies are being developed to target cancer cells that over-express the folate receptor.
- Conditions
- Recurrent or Metastatic Cancer, Head and Neck Cancer, Pancreas Cancer, Bladder Cancer
- Trial name
- NCT01684098
- Testing
- Tc 99m EC20
- Volunteers
- 40 people
- Sponsor
- Endocyte
Bladder Cancer Cell Transitional, Non-Muscle Invasive Bladder Cancer
Proliposomal Intravesical Paclitaxel for Treatment of Low-Grade, Stage Ta, Non Muscle Invasive Bladder Cancer
This is a single-arm, phase 1/2a study of formulated paclitaxel in subjects with low-grade, noninvasive papillary carcinoma (stage Ta) of the bladder.
- Conditions
- Bladder Cancer Cell Transitional, Non-Muscle Invasive Bladder Cancer, Bladder Cancer, Urinary Bladder
- Trial name
- NCT03081858
- Testing
- TSD-001
- Where
- 5 sites in United States
- Volunteers
- 15 people
- Sponsor
- Lipac Oncology LLC
Metastatic Solid Tumor, Recurrent Solid Tumor
A Study of LY4101174 in Participants With Recurrent, Advanced or Metastatic Solid Tumors
The purpose of this study is to find out whether the study drug, LY4101174, is safe, tolerable and effective in participants with select advanced or metastatic solid tumors.
- Conditions
- Metastatic Solid Tumor, Recurrent Solid Tumor, Advanced Solid Tumor, Urinary Bladder Neoplasm
- Trial name
- EXCEED (NCT06238479)
- Testing
- LY4101174
- Where
- 28 sites in United States, Australia and 5 more
- Volunteers
- 490 people
- Sponsor
- Eli Lilly and Company
Urinary Tract Infection (UTI), Complicated Urinary Tract Infection
Study of Ceftolozane/Tazobactam (MK-7625A) in Japanese Participants With Uncomplicated Pyelonephritis and Complicated Urinary Tract Infection (MK-7625A-014)
This is a Phase 3, multi-site, non-randomized, open-label study evaluating the safety and efficacy of MK-7625A 1.5 g (ceftolozane 1 g/tazobactam 0.5 g) for the treatment of complicated urinary tract infection (cUTI) including…
- Conditions
- Urinary Tract Infection (UTI), Complicated Urinary Tract Infection, Pyelonephritis, Uncomplicated Pyelonephritis
- Trial name
- NCT02728089
- Testing
- MK-7625A 1.5 g (ceftolozane 1 g/tazobactam 0.5 g)
- Volunteers
- 115 people
- Sponsor
- Merck Sharp & Dohme LLC
Thyroid Cancer, Renal Cell Carcinoma
Study of Nanrilkefusp Alfa Alone and With Pembrolizumab in Adult Patients With Advanced/Metastatic Solid Tumors
A multicenter open-label phase 1/1b study to evaluate the safety and preliminary efficacy of nanrilkefusp alfa as monotherapy and in combination with pembrolizumab in patients with selected advanced/metastatic solid tumors
- Conditions
- Thyroid Cancer, Renal Cell Carcinoma, Non Small Cell Lung Cancer, Small-cell Lung Cancer
- Trial name
- NCT04234113
- Testing
- Nanrilkefusp alfa, Pembrolizumab
- Where
- 12 sites in United States, Czechia and 2 more
- Volunteers
- 115 people
- Sponsor
- SOTIO Biotech AG
Urinary Incontinence, Urinary Incontinence, Urge
Safety and Performance of UCon Patch Electrode
UCon is a medical device for treating the symptoms of overactive bladder (OAB) and bowel dysfunction (BD). It electrically stimulates the DGN through the skin to obtain modulated behavior of the bladder/bowel musculature e.g.…
- Conditions
- Urinary Incontinence, Urinary Incontinence, Urge, Nocturia, Urinary Frequency More Than Once at Night
- Trial name
- NCT06754189
- Testing
- Time Limited stimulation
- Where
- 3 sites in Denmark
- Volunteers
- 180 people
- Sponsor
- InnoCon Medical
Neurogenic Bladder Disorder, Non-Neurogenic Bladder
Define Final Selection Choice Criteria for a Coloplast Catheter Ensuring Highest Patient Satisfaction Via Surveys (EVA).
Understanding the Coloplast Intermittent Catheter Selection Study: This study aims to understand how adults who need to use catheters to empty their bladder by themselves decide which Coloplast catheter works best for them.
- Conditions
- Neurogenic Bladder Disorder, Non-Neurogenic Bladder, Bladder Dysfunction, Urinary Retention
- Trial name
- EVA (NCT07355803)
- Testing
- Questionnaires : Patient questionnaire on catheter use and satisfaction, IC-Di-Q, and I-CAT
- Where
- Belgium
- Volunteers
- 22 people
- Sponsor
- Coloplast NV/SA
Urinary Calculi, Urinary Stones
Pharmacokinetic, Safety and Efficacy Study of OMS201 in Subjects Undergoing Retrograde Ureteroscopic Removal of Upper Urinary Tract Stones
The objectives of the study are to assess the systemic exposure, safety and efficacy of three concentrations of OMS201 in subjects undergoing retrograde ureteroscopic removal of upper urinary tract stones.
- Conditions
- Urinary Calculi, Urinary Stones, Urinary Tract Stones, Renal Calculi
- Trial name
- NCT00857090
- Testing
- OMS201, Vehicle
- Where
- 4 sites in United States
- Volunteers
- 18 people
- Sponsor
- Omeros Corporation
Urinary Tract Infection
Safety and Tolerability of Ertapenem Sodium in the Treatment of Complicated Urinary Tract Infections (0826-055)
The purpose of this study is to determine the efficacy of ertapenem sodium (Invanz) in treatment of complicated urinary tract infections with respect to the proportion of patients with a favorable microbiological response at 5-9…
- Trial name
- NCT01014013
- Testing
- ertapenem sodium (MK0826), Comparator: ceftriaxone sodium
- Volunteers
- 271 people
- Sponsor
- Merck Sharp & Dohme LLC